Maintaining bioactivity of NGF for controlled release from PLGA using PEG

Philip J. Johnson, Stacy L. Skornia, Sarah Stabenfeldt, Rebecca Kuntz Willits

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The goal of this work was to investigate methods to retain bioactivity of nerve growth factor (NGF) after encapsulation in poly(lactic-co-glycolic acid) (PLGA) discs for controlled release. Poly(ethylene glycol) (PEG) was chosen as a porogen not only to control the release rate of NGF but also because it has been used to help maintain bioactivity of molecules in organic solvents. NGF and PEG were encapsulated in PLGA via standard dissolution-evaporation techniques with methylene chloride as the solvent. Morita et al. (Pharm Res 2000; 17:1367-1373) indicated that colyophilization of PEG and bioactive factors before exposure to organic solvents increased the retention of bioactivity. Therefore, various PEG:NGF mass ratios were colyophilized before encapsulation within PLGA to examine retained activity of NGF. When PEG was not colyophilized before encapsulation, NGF activity was lost during the fabrication process. In contrast, colyophilization of PEG and NGF supported retention of NGF activity during the entire fabrication process. The amount of PEG encapsulated was the dominating factor in the rate of NGF release regardless of the fabrication method. These results demonstrate the usefulness of PEG in both acting as a porogen to modulate release and aiding in the retention of activity of NGF. This process may be extended to other methods to enhance activity of growth factors after exposure to organic solvents.

Original languageEnglish (US)
Pages (from-to)420-427
Number of pages8
JournalJournal of Biomedical Materials Research - Part A
Volume86
Issue number2
DOIs
StatePublished - Aug 2008
Externally publishedYes

Fingerprint

Nerve Growth Factor
Bioactivity
Polyethylene glycols
Acids
Encapsulation
Organic solvents
Fabrication
polylactic acid-polyglycolic acid copolymer
Intercellular Signaling Peptides and Proteins
Milk
Methylene Chloride
Dichloromethane
Dissolution
Evaporation
Molecules

Keywords

  • Bioactivity
  • Nerve growth factor
  • Poly(ethylene glycol)
  • Poly(lactic-co-glycolic acid)

ASJC Scopus subject areas

  • Biomedical Engineering
  • Biomaterials

Cite this

Maintaining bioactivity of NGF for controlled release from PLGA using PEG. / Johnson, Philip J.; Skornia, Stacy L.; Stabenfeldt, Sarah; Willits, Rebecca Kuntz.

In: Journal of Biomedical Materials Research - Part A, Vol. 86, No. 2, 08.2008, p. 420-427.

Research output: Contribution to journalArticle

Johnson, Philip J. ; Skornia, Stacy L. ; Stabenfeldt, Sarah ; Willits, Rebecca Kuntz. / Maintaining bioactivity of NGF for controlled release from PLGA using PEG. In: Journal of Biomedical Materials Research - Part A. 2008 ; Vol. 86, No. 2. pp. 420-427.
@article{a0370ba2240f4cddb959c093b9057097,
title = "Maintaining bioactivity of NGF for controlled release from PLGA using PEG",
abstract = "The goal of this work was to investigate methods to retain bioactivity of nerve growth factor (NGF) after encapsulation in poly(lactic-co-glycolic acid) (PLGA) discs for controlled release. Poly(ethylene glycol) (PEG) was chosen as a porogen not only to control the release rate of NGF but also because it has been used to help maintain bioactivity of molecules in organic solvents. NGF and PEG were encapsulated in PLGA via standard dissolution-evaporation techniques with methylene chloride as the solvent. Morita et al. (Pharm Res 2000; 17:1367-1373) indicated that colyophilization of PEG and bioactive factors before exposure to organic solvents increased the retention of bioactivity. Therefore, various PEG:NGF mass ratios were colyophilized before encapsulation within PLGA to examine retained activity of NGF. When PEG was not colyophilized before encapsulation, NGF activity was lost during the fabrication process. In contrast, colyophilization of PEG and NGF supported retention of NGF activity during the entire fabrication process. The amount of PEG encapsulated was the dominating factor in the rate of NGF release regardless of the fabrication method. These results demonstrate the usefulness of PEG in both acting as a porogen to modulate release and aiding in the retention of activity of NGF. This process may be extended to other methods to enhance activity of growth factors after exposure to organic solvents.",
keywords = "Bioactivity, Nerve growth factor, Poly(ethylene glycol), Poly(lactic-co-glycolic acid)",
author = "Johnson, {Philip J.} and Skornia, {Stacy L.} and Sarah Stabenfeldt and Willits, {Rebecca Kuntz}",
year = "2008",
month = "8",
doi = "10.1002/jbm.a.31635",
language = "English (US)",
volume = "86",
pages = "420--427",
journal = "Journal of Biomedical Materials Research - Part B Applied Biomaterials",
issn = "0021-9304",
publisher = "Heterocorporation",
number = "2",

}

TY - JOUR

T1 - Maintaining bioactivity of NGF for controlled release from PLGA using PEG

AU - Johnson, Philip J.

AU - Skornia, Stacy L.

AU - Stabenfeldt, Sarah

AU - Willits, Rebecca Kuntz

PY - 2008/8

Y1 - 2008/8

N2 - The goal of this work was to investigate methods to retain bioactivity of nerve growth factor (NGF) after encapsulation in poly(lactic-co-glycolic acid) (PLGA) discs for controlled release. Poly(ethylene glycol) (PEG) was chosen as a porogen not only to control the release rate of NGF but also because it has been used to help maintain bioactivity of molecules in organic solvents. NGF and PEG were encapsulated in PLGA via standard dissolution-evaporation techniques with methylene chloride as the solvent. Morita et al. (Pharm Res 2000; 17:1367-1373) indicated that colyophilization of PEG and bioactive factors before exposure to organic solvents increased the retention of bioactivity. Therefore, various PEG:NGF mass ratios were colyophilized before encapsulation within PLGA to examine retained activity of NGF. When PEG was not colyophilized before encapsulation, NGF activity was lost during the fabrication process. In contrast, colyophilization of PEG and NGF supported retention of NGF activity during the entire fabrication process. The amount of PEG encapsulated was the dominating factor in the rate of NGF release regardless of the fabrication method. These results demonstrate the usefulness of PEG in both acting as a porogen to modulate release and aiding in the retention of activity of NGF. This process may be extended to other methods to enhance activity of growth factors after exposure to organic solvents.

AB - The goal of this work was to investigate methods to retain bioactivity of nerve growth factor (NGF) after encapsulation in poly(lactic-co-glycolic acid) (PLGA) discs for controlled release. Poly(ethylene glycol) (PEG) was chosen as a porogen not only to control the release rate of NGF but also because it has been used to help maintain bioactivity of molecules in organic solvents. NGF and PEG were encapsulated in PLGA via standard dissolution-evaporation techniques with methylene chloride as the solvent. Morita et al. (Pharm Res 2000; 17:1367-1373) indicated that colyophilization of PEG and bioactive factors before exposure to organic solvents increased the retention of bioactivity. Therefore, various PEG:NGF mass ratios were colyophilized before encapsulation within PLGA to examine retained activity of NGF. When PEG was not colyophilized before encapsulation, NGF activity was lost during the fabrication process. In contrast, colyophilization of PEG and NGF supported retention of NGF activity during the entire fabrication process. The amount of PEG encapsulated was the dominating factor in the rate of NGF release regardless of the fabrication method. These results demonstrate the usefulness of PEG in both acting as a porogen to modulate release and aiding in the retention of activity of NGF. This process may be extended to other methods to enhance activity of growth factors after exposure to organic solvents.

KW - Bioactivity

KW - Nerve growth factor

KW - Poly(ethylene glycol)

KW - Poly(lactic-co-glycolic acid)

UR - http://www.scopus.com/inward/record.url?scp=47049098671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47049098671&partnerID=8YFLogxK

U2 - 10.1002/jbm.a.31635

DO - 10.1002/jbm.a.31635

M3 - Article

C2 - 17969039

AN - SCOPUS:47049098671

VL - 86

SP - 420

EP - 427

JO - Journal of Biomedical Materials Research - Part B Applied Biomaterials

JF - Journal of Biomedical Materials Research - Part B Applied Biomaterials

SN - 0021-9304

IS - 2

ER -